Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00008697 · ClinicalTrials.gov registry record · Phase 1

Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia

A Phase 1 study of Leukemia, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target
1
Study location

NCT00008697 is a Phase 1 study of Leukemia that has completed, run by Washington University School of Medicine. The registered enrollment target is 13 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00008697, a Phase 1 study of Leukemia, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate both the efficacy and toxicity of infusional arsenic trioxide in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APML). In addition, correlation between pharmacokinetic data and both therapeutic response and therapy-related toxicities will be sought.

Conditions Studied

Leukemia

Interventions

  • DRUG arsenic trioxide

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 1998-11
Est. Completion 2002-04
Phase Phase 1

Sponsor

Washington University School of Medicine

1,502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00008697

The ClinicalTrials.gov registry entry for NCT00008697 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which arsenic trioxide is the first listed.

NCT00008697 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT00008697 about?

NCT00008697 is a clinical study titled "Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia". The purpose of this study is to evaluate both the efficacy and toxicity of infusional arsenic trioxide in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APML). In addition, correlation between pharmacokinetic data and both therapeutic response and therapy-related...

What is the current status of trial NCT00008697?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 1998-11. Estimated completion is 2002-04.

What conditions does trial NCT00008697 study?

This clinical trial studies the following conditions: Leukemia.

What interventions are being tested in trial NCT00008697?

The interventions under investigation include: arsenic trioxide (DRUG).

Who is sponsoring clinical trial NCT00008697?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00008697 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Leukemia

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.